The relation between serum levels of interleukin 10 and interferon-gamma with oral candidiasis in type 2 diabetes mellitus patients

[1]  Bader K AlZarea,et al.  Prevalence of Oral Candidiasis in Diabetic Patients at Northern of Kingdom of Saudi Arabia , 2020 .

[2]  J. Shaw,et al.  Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. , 2019, Diabetes research and clinical practice.

[3]  C. F. Rodrigues,et al.  Candida sp. Infections in Patients with Diabetes Mellitus , 2019, Journal of clinical medicine.

[4]  Kathy O. Lui,et al.  Regulatory T Cells Promote Apelin-Mediated Sprouting Angiogenesis in Type 2 Diabetes. , 2018, Cell reports.

[5]  M. Peters,et al.  Yoga and immune system functioning: a systematic review of randomized controlled trials , 2018, Journal of Behavioral Medicine.

[6]  S. Mohammadi,et al.  Glucocorticoid-induced leucine zipper expression is associated with response to treatment and immunoregulation in systemic lupus erythematosus , 2017, Clinical Rheumatology.

[7]  M. W. Marshall,et al.  Oral Fungal Infections: Diagnosis and Management. , 2017, Dental clinics of North America.

[8]  K. Zomorodian,et al.  Prevalence of oral Candida colonization in patients with diabetes mellitus. , 2016, Journal de mycologie medicale.

[9]  Samita Giri,et al.  Identification of Candida species using CHROM agar. , 2016, International Journal of Medicine and Biomedical Sciences.

[10]  Shukla Das,et al.  Interleukin-10 as an indicator of chronic course of oral candidiasis in diabetics: an in vitro study , 2016, International Journal of Diabetes in Developing Countries.

[11]  H. Kurita,et al.  Candida concentrations determined following concentrated oral rinse culture reflect clinical oral signs , 2015, BMC oral health.

[12]  Chih-Cheng Lai,et al.  Epidemiology and prognostic factors of candidemia in elderly patients , 2015, Geriatrics & gerontology international.

[13]  J. Bagan,et al.  Current treatment of oral candidiasis: A literature review , 2014, Journal of clinical and experimental dentistry.

[14]  P. Shetty,et al.  A comparative study of oral candidal species carriage in patients with type1 and type2 diabetes mellitus , 2014, Journal of oral and maxillofacial pathology : JOMFP.

[15]  R. Verma,et al.  Oral candidiasis: An overview , 2014, Journal of oral and maxillofacial pathology : JOMFP.

[16]  Aitao Guo,et al.  Association between interleukin 10 gene polymorphisms and risk of type 2 diabetes mellitus in a Chinese population , 2014, The Journal of international medical research.

[17]  M. Netea,et al.  Interferon-gamma as adjunctive immunotherapy for invasive fungal infections: a case series , 2014, BMC Infectious Diseases.

[18]  P. Ramani,et al.  Detection of species diversity in oral candida colonization and anti-fungal susceptibility among non-oral habit adult diabetic patients , 2014, Journal of natural science, biology, and medicine.

[19]  Jie Shen,et al.  Interleukin-10 −592C/A, −819C/T and −1082A/G Polymorphisms with Risk of Type 2 Diabetes Mellitus: A HuGE Review and Meta-analysis , 2013, PloS one.

[20]  C. Alves,et al.  Infections in patients with diabetes mellitus: A review of pathogenesis , 2012, Indian journal of endocrinology and metabolism.

[21]  S. Iyer,et al.  Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. , 2012, Critical reviews in immunology.

[22]  M. Mahmoodi,et al.  Serum Levels of Interleukin 10 (IL-10) in Patients with Type 2 Diabetes , 2011, Iranian Red Crescent medical journal.

[23]  C. Koga‐Ito,et al.  Prevalence and antifungal resistance profile of Candida spp. oral isolates from patients with type 1 and 2 diabetes mellitus. , 2011, Archives of oral biology.

[24]  A. Liston,et al.  A new role for interleukin‐10 in immune regulation , 2010, Immunology and Cell Biology.

[25]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[26]  H. Cohen,et al.  IFN‐γ enhances neurogenesis in wild‐type mice and in a mouse model of Alzheimer's disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  H. Shokri,et al.  Factors affecting the prevalence of yeasts in the oral cavity of patients with diabetes mellitus , 2008 .

[28]  L. Carvalho,et al.  Microbiological and Immunological Features of Oral Candidiasis , 2007, Microbiology and immunology.

[29]  K. Abu-Elteen,et al.  Prevalence of Oral Candida Infections in Diabetic Patients , 2006 .

[30]  A. Velegraki,et al.  Candidal overgrowth in diabetic patients: potential predisposing factors , 2005, Mycoses.

[31]  M. S. Rao,et al.  Prevalence of Candida in the oral cavity of diabetic subjects. , 2005, The Journal of the Association of Physicians of India.

[32]  M. Schaller,et al.  Polymorphonuclear leukocytes (PMNs) induce protective Th1-type cytokine epithelial responses in an in vitro model of oral candidosis. , 2004, Microbiology.

[33]  A. D. de Craen,et al.  Low production capacity of interleukin-10 associates with the metabolic syndrome and type 2 diabetes : the Leiden 85-Plus Study. , 2002, Diabetes.

[34]  J. Gussekloo,et al.  The Leiden 85-plus Study , 2000 .

[35]  T. Walsh,et al.  Suppressive effects of interleukin-10 on human mononuclear phagocyte function against Candida albicans and Staphylococcus aureus. , 1998, The Journal of infectious diseases.

[36]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[37]  A. Szkaradkiewicz,et al.  Serum interferon-gamma (IFN-c) in chronic oral candidosis , 1998 .

[38]  L. Samaranayake,et al.  The relationship between colonisation, secretor status and in-vitro adhesion of Candida albicans to buccal epithelial cells from diabetics. , 1990, Journal of medical microbiology.